Synopsis
Synopsis
0
API Suppliers
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
NDC API
0
VMF
0
Listed Suppliers
0
EDQM
0
USP
0
JP
0
Others
0
FDF Dossiers
0
FDA Orange Book
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
US Patents
0
US Exclusivities
0
Health Canada Patents
US Medicaid
NA
Annual Reports
NA
Regulatory FDF Prices
NA
0
API
0
FDF
0
Data Compilation #PharmaFlow
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
1. Deucrictibant [inn]
2. 69gca2kx22
3. Pha-121
4. Unii-69gca2kx22
5. Phvs-719
6. Pha-022121
7. 2340111-58-0
8. (s)-n-(1-deutero-1-(3-chloro-5-fluoro-2-((2-methyl-4-(1-methyl-1h-1,2,4-triazol-5-yl)quinolin-8-yloxy)methyl)phenyl)ethyl)-2-(difluoromethoxy)acetamide
9. Acetamide, N-((1s)-1-(3-chloro-5-fluoro-2-(((2-methyl-4-(1-methyl-1h-1,2,4-triazol-5-yl)-8-quinolinyl)oxy)methyl)phenyl)ethyl-1-d)-2-(difluoromethoxy)-
10. Chembl5095059
11. Schembl22320140
12. Gtpl12421
13. Glxc-26832
14. Pha022121
15. Hy-145562
16. Cs-0376051
17. N-[(1s)-1-[3-chloro-5-fluoro-2-({[2-methyl-4-(1-methyl-1h-1,2,4-triazol-5-yl)quinolin-8-yl]oxy}methyl)phenyl](1-2h)ethyl]-2-(difluoromethoxy)acetamide
18. N-[(1s)-1-[3-chloro-5-fluoro-2-[[2-methyl-4-(2-methyl-1,2,4-triazol-3-yl)quinolin-8-yl]oxymethyl]phenyl]-1-deuterioethyl]-2-(difluoromethoxy)acetamide
| Molecular Weight | 534.9 g/mol |
|---|---|
| Molecular Formula | C25H23ClF3N5O3 |
| XLogP3 | 4.9 |
| Hydrogen Bond Donor Count | 1 |
| Hydrogen Bond Acceptor Count | 9 |
| Rotatable Bond Count | 9 |
| Exact Mass | g/mol |
| Monoisotopic Mass | g/mol |
| Topological Polar Surface Area | 91.2 |
| Heavy Atom Count | 37 |
| Formal Charge | 0 |
| Complexity | 758 |
| Isotope Atom Count | 1 |
| Defined Atom Stereocenter Count | 1 |
| Undefined Atom Stereocenter Count | 0 |
| Defined Bond Stereocenter Count | 0 |
| Undefined Bond Stereocenter Count | 0 |
| Covalently Bonded Unit Count | 1 |
Drugs in Development
Details:
PHVS416 (deucrictibant) is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist currently in development to prevent the occurrence of bradykinin-mediated angioedema attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 01, 2025
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces Orphan Designation Granted to Deucrictibant by the European Commission
Details : PHVS416 (deucrictibant) is a novel, potent, oral small-molecule bradykinin B2 receptor antagonist currently in development to prevent the occurrence of bradykinin-mediated angioedema attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 01, 2025
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor, which is being evaluated for the treatment of hereditary angioedema attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 18, 2024
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces Phase 3 Design for RAPIDe-3 Study and Presents HAE Study Data
Details : PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor, which is being evaluated for the treatment of hereditary angioedema attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 18, 2024
Details:
PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. It is being evaluated in phase 2/3 trials for the prophylactic treatment of HAE Attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable January 22, 2024
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Lifted Clinical Hold on Deucrictibant for HAE Attack Prophylactic Treatment
Details : PHVS416 (deucrictibant) is a potent, selective, and orally available antagonist of the bradykinin B2 receptor. It is being evaluated in phase 2/3 trials for the prophylactic treatment of HAE Attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 22, 2024
Details:
PHVS416 (deucrictibant) is an investigational softgel immediate-release capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, which is investigated for HAE attacks.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 26, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 (deucrictibant) is an investigational softgel immediate-release capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, which is investigated for HAE attacks.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 26, 2023
Details:
Pharvaris will use the net proceeds to fund research and development of its drug candidates including, PHVS416 (deucrictibant), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, being developed for hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: General Atlantic
Deal Size: $70.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement June 20, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : General Atlantic
Deal Size : $70.0 million
Deal Type : Private Placement
Pharvaris Announces $70 Million Private Placement Financing
Details : Pharvaris will use the net proceeds to fund research and development of its drug candidates including, PHVS416 (deucrictibant), a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor, being developed for h...
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 20, 2023
Details:
PHVS416 (deucrictibant) is a bradykinin B2 receptor inhibitor small molecule drug candidate in oral soft gel capsule form for prophylaxis against hereditary angioedema.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable June 12, 2023
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 (deucrictibant) is a bradykinin B2 receptor inhibitor small molecule drug candidate in oral soft gel capsule form for prophylaxis against hereditary angioedema.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 12, 2023
Details:
Pharmacokinetic properties of PHA121 were evaluated to support the intended therapeutic use of PHVS719 for the prophylactic treatment of HAE attacks using preclinical and clinical experimental models.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable October 11, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Pharmacokinetic properties of PHA121 were evaluated to support the intended therapeutic use of PHVS719 for the prophylactic treatment of HAE attacks using preclinical and clinical experimental models.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 11, 2022
Details:
The data demonstrate that PHA121 (aka PHVS416), is 25-fold more potent than icatibant at inhibiting bradykinin interaction with the endogenous human B2 receptor.PHA121 is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 16, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The data demonstrate that PHA121 (aka PHVS416), is 25-fold more potent than icatibant at inhibiting bradykinin interaction with the endogenous human B2 receptor.PHA121 is a highly potent, specific, and orally bioavailable competitive antagonist of the br...
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2022
Details:
PHVS416/PHA121 (PHA-022121) is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor that has completed Phase 1 clinical development for the treatment of HAE.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase IIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 22, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharvaris Announces FDA Clinical Hold on PHA121 Clinical Trials in the U.S.
Details : PHVS416/PHA121 (PHA-022121) is a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor that has completed Phase 1 clinical development for the treatment of HAE.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 22, 2022
Details:
PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Lead Product(s): Deucrictibant
Therapeutic Area: Genetic Disease Brand Name: PHVS416
Study Phase: Phase II/ Phase IIIProduct Type: Other Small Molecule
Sponsor: Inapplicable
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 12, 2022
Lead Product(s) : Deucrictibant
Therapeutic Area : Genetic Disease
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : PHVS416 is an investigational softgel capsule formulation containing PHA121, a highly potent, specific, and orally bioavailable competitive antagonist of the bradykinin B2 receptor.
Product Name : PHVS416
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 12, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]Digital Content
NEWS #PharmaBuzz
ABOUT THIS PAGE
29
PharmaCompass offers a list of Deucrictibant API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, Price,and more, enabling you to easily find the right Deucrictibant manufacturer or Deucrictibant supplier for your needs.
Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Deucrictibant manufacturer or Deucrictibant supplier.
PharmaCompass also assists you with knowing the Deucrictibant API Price utilized in the formulation of products. Deucrictibant API Price is not always fixed or binding as the Deucrictibant Price is obtained through a variety of data sources. The Deucrictibant Price can also vary due to multiple factors, including market conditions, regulatory modifications, or negotiated pricing deals.
A Deucrictibant manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Deucrictibant, including repackagers and relabelers. The FDA regulates Deucrictibant manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Deucrictibant API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
A Deucrictibant supplier is an individual or a company that provides Deucrictibant active pharmaceutical ingredient (API) or Deucrictibant finished formulations upon request. The Deucrictibant suppliers may include Deucrictibant API manufacturers, exporters, distributors and traders.
Deucrictibant Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Deucrictibant GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Deucrictibant GMP manufacturer or Deucrictibant GMP API supplier for your needs.
A Deucrictibant CoA (Certificate of Analysis) is a formal document that attests to Deucrictibant's compliance with Deucrictibant specifications and serves as a tool for batch-level quality control.
Deucrictibant CoA mostly includes findings from lab analyses of a specific batch. For each Deucrictibant CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Deucrictibant may be tested according to a variety of international standards, such as European Pharmacopoeia (Deucrictibant EP), Deucrictibant JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Deucrictibant USP).
